BTBP(SH:600161) Xin Lang Cai Jing·2025-08-05 09:02Core Viewpoint - TianTan Biological announced that its subsidiary Chengdu RongSheng Pharmaceutical has completed clinical trials for its product "Recombinant Human Coagulation Factor VIII for Injection" in children under 12 years old, demonstrating good safety and efficacy for treating Hemophilia A patients in this age group [1] Group 1 - The product is primarily used for controlling and preventing bleeding in patients with Hemophilia A under 12 years old [1] - Routine preventive treatment with this product significantly reduces bleeding frequency and improves joint health scores, target joint count, and quality of life scores for patients [1] - Safety analysis indicates that the drug has good safety profiles during clinical application for this demographic [1]